Full text is available at the source.
Abstract
GLP-1 receptor agonists like semaglutide may cause significant loss of muscle mass in obesity models.
- Semaglutide treatment is associated with decreased skeletal muscle mass in mice on a high-fat diet.
- Despite the loss of muscle mass, contractile function remains intact with semaglutide use.
- Muscle regeneration and strength recovery following injury are impaired by semaglutide treatment.
- This impairment in muscle recovery is linked to reduced function of muscle stem cells.
- Co-treatment with an inhibitor of a specific enzyme boosts muscle mass and improves regeneration when combined with semaglutide.
Simplified